GSK

Save the Children and GlaxoSmithKline launched a five-year strategic global partnership (2013-2017) combining their expertise, resources and influence to help save the lives of one million of the poorest children in the world. This unique collaboration will see the two organizations working to tackle some of the leading causes of child mortality.


Program Support

GSK supports model flagship programs in the Democratic Republic of Congo and Kenya to tackle child mortality that can be adopted, expanded and replicated in other developing countries. Learn More

New Product Development

Through our partnership, GSK and Save the Children are working together to accelerate the availability of life-saving medicines designed especially for children. Learn More

Employee Engagement

Employees around the world are encouraged to take an active role in the partnership through both fundraising and the sharing of skills and expertise. Learn More


Program Support

Currently, more than 6 million children under age 5 die every year from preventable diseases. In the last ten years, significant progress has been made globally to reduce the rate of child deaths; however, more needs to be done to prevent children from dying unnecessarily.

GSK supports Save the Children’s model programs working to develop child-friendly medicines to reduce child mortality and newborn deaths, widening vaccination coverage and increasing training of health workers in the poorest, hardest-to-reach communities. Our flagship country programs, initially launched in the Democratic Republic of Congo and Kenya, include these interventions and are now being monitored and evaluated to allow the partnership to scale up and tackle child mortality in other developing countries.


New Product Development

Developing child-friendly medicines to reduce child mortality and newborn deaths

Through our partnership, GSK and Save the Children are working together to accelerate the availability of life-saving medicines designed especially for children. Save the Children will be involved in helping GSK to research and develop medicines for children under age 5, as well as identifying ways to ensure the widest possible access to medicines in the developing world. GSK will be able to leverage Save the Children's child health expertise and on-the-ground experience to reach children with basic health care, even in the most remote and marginalized communities.

Products include the antiseptic chlorhexidine – commonly used in mouthwash – which will be reformulated into a gel for cleansing the umbilical cord stump of newborn babies to prevent serious infection, a major cause of newborn death in poor countries.

Uniting a Global Workforce

Save the Children also benefits from PULSE, GSK’s skills-based volunteering program, through which GSK gives their greatest resource – people – to contribute real and lasting value to their partners and the communities they serve. With sustainability as a key focus of the PULSE program, GSK employees around the world are encouraged to take an active role in the Save the Children partnership through both fundraising and the sharing of skills and expertise. In 2014, 18 GSK employees were assigned to Save the Children offices globally, including locations in Peru, the Philippines, Kenya and the UK.

Twitter Facebook Pinterest Google+ More